Buriolla, Silvia;
Cavalieri, Stefano;
Franza, Andrea;
Rota, Simone;
Bergamini, Cristiana;
Alfieri, Salvatore;
Nuzzolese, Imperia;
Colombo, Elena;
Ottini, Arianna;
Licitra, Lisa F.;
Resteghini, Carlo
Clinical characterization of responders to first line (chemo)immunotherapy in platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC)
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Clinical characterization of responders to first line (chemo)immunotherapy in platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC)
Beteiligte:
Buriolla, Silvia;
Cavalieri, Stefano;
Franza, Andrea;
Rota, Simone;
Bergamini, Cristiana;
Alfieri, Salvatore;
Nuzzolese, Imperia;
Colombo, Elena;
Ottini, Arianna;
Licitra, Lisa F.;
Resteghini, Carlo
Erschienen:
American Society of Clinical Oncology (ASCO), 2023
Beschreibung:
<jats:p> e18017 </jats:p><jats:p> Background: RM HNSCC patients (pts) with combined positive score (CPS) ≥1 benefit from immunotherapy (IO), either alone or with chemotherapy (CIO). No survival outcome indicators are available. We aim to characterize a real world cohort of RM HNSCC pts treated at a tertiary cancer center. Methods: We analyzed 37 consecutive RM HNSCC pts treated with IO or CIO from 2016 to 2022. We divided pts in responders (R) and non responders (NR) if they achieved an objective response or disease stability/progression as best response. For group comparisons, we considered the following clinical variables: age, gender, smoking status, primary HNSCC site, HPV status, ECOG performance status, disease sites at RM diagnosis (local, regional, distant), time to RM diagnosis (TTR). For categorical variables, we compared the clinical characteristics of the 2 groups using the chi squared or Fisher’s exact tests, as appropriate. For age we used the Mann-Whitney test. For TTR we used the Cox proportional hazard model. Outcomes (progression free and overall survival, PFS and OS, respectively) were assessed with Kaplan Meier method and compared with log-rank test. Statistical significance was set at 0.05. Results: Clinical characteristics are reported in the table. Objective response rate (ORR) was 32%, median DoR 7.5 months (95% confidence interval, CI 2.07-not reached). None of the examined clinical variables were significantly different in the groups (R vs NR in the overall population, in IO- and CIO-treated pts). The only major difference between cohorts was survival, which was significantly longer in R vs non-R (Table). Conclusions: With the limits of a retrospective analysis, we observed a longer survival in R compared to NR. None of the main clinical characteristics were predictive of objective response to (C)IO. Further studies are needed to define predictive factors of response, and to enhance the ORR in first-line IO-based treatments. [Table: see text] </jats:p>